A little over a year ago, Harvard University’s Harvard Medical School professors Isaac Kohane, MD, PhD, and David Margulies, MD, hosted a meeting to advocate that the collective experience of researchers and clinicians with gene variants needs to be moved to the precompetitive space. According to Margulies, having universal open access to all data from sequence-derived assays is a safety matter. “It’s no less critical an issue,” he says, “than airlines’ sharing of aircraft safety data with each other for the public good and voluntarily deciding not to compete based on innuendo about unproven safety issues.”
The upshot of this sentiment has been a ratcheting up of discussions around potential venues for genomic data storage and sharing, the degree of cooperation to anticipate from clinical labs, and what the sustainability model might be both for labs that participate in such open-access efforts and for companies that offer enabling workflow tools
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
